Paper Details

  1. Home
  2. Paper Details

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.

Author: BorlandJulie, ChenShuguang, JohnsonMark, PiscitelliStephen, SavinaPaul, WynneBrian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolutegravir can be coadministered with boceprevir or telaprevir in patients coinfected with HIV and HCV with no dose adjustment.
Paper Details　
Original Abstract of the Article :
AIMS: The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with historical data for each hepatitis C virus (HCV) drug's prescribing information alone. METHODS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243878/

データ提供：米国国立医学図書館（NLM）

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

The co-infection of HIV and hepatitis C virus (HCV) presents a significant challenge in managing viral infections. This study investigates the potential drug interactions between dolutegravir, an antiretroviral medication, and boceprevir and telaprevir, two HCV protease inhibitors. The researchers explored the pharmacokinetic interactions between these medications in a controlled setting.

Understanding Drug Interactions in HIV/HCV Co-infection

This study provides valuable information about the pharmacokinetic interactions between dolutegravir, boceprevir, and telaprevir. The researchers' findings suggest that dolutegravir can be safely co-administered with these HCV protease inhibitors without requiring dose adjustments. This information is critical for optimizing treatment strategies for patients with HIV/HCV co-infection.

Navigating the Complex Terrain of Viral Treatment

The study's findings offer practical guidance for managing HIV/HCV co-infection. The researchers' exploration of drug interactions provides a more precise understanding of the pharmacokinetic interplay between these medications. It's like having a compass to guide through the complex terrain of viral treatment, helping to ensure effective and safe treatment strategies for patients.

Dr.Camel's Conclusion

This study provides valuable insights into the pharmacokinetic interactions between dolutegravir, boceprevir, and telaprevir. The findings suggest that dolutegravir can be safely co-administered with these HCV protease inhibitors without requiring dose adjustments. This information is crucial for optimizing treatment strategies for patients with HIV/HCV co-infection, potentially improving treatment outcomes and overall patient well-being.
Date :
  1. Date Completed 2015-07-29
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24838177

DOI: Digital Object Identifier

PMC4243878

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.